36611
document
Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients : a double-blind , randomized cross-over study . PURPOSE Breast cancer patients with treatment-induced menopause experience frequent and severe hot flashes ( HF ) . We compared venlafaxine and clonidine for the treatment of HF with regard to side effects , efficacy , quality of life and sexual functioning . METHODS In a double-blind , cross-over study , 60 breast cancer patients experiencing HF were randomized to 8 weeks venlafaxine followed by 2 weeks wash-out , and 8 weeks clonidine or vice versa . HF frequency and severity , side effects , quality of life and sexuality were assessed . RESULTS Thirty patients started with venlafaxine and 30 with clonidine . Premature discontinuation for toxicity occurred in 14/59 during venlafaxine and 5/53 during clonidine ( P = .038 ) . Venlafaxine induced more side effects . Median reduction in HF score was 49 % for venlafaxine and 55 % for clonidine ( ns ) . CONCLUSION Venlafaxine and clonidine are equally , but moderately effective in HF reduction . Side effects are the main reason for drug discontinuation , occurring more often with venlafaxine .
36612
Intervention_Pharmacological
Venlafaxine
36613
Intervention_Pharmacological
clonidine
36614
Intervention_Pharmacological
venlafaxine
36615
Intervention_Pharmacological
clonidine
36616
Intervention_Pharmacological
venlafaxine
36617
Intervention_Pharmacological
clonidine
36618
Intervention_Pharmacological
venlafaxine
36619
Intervention_Pharmacological
clonidine
36620
Intervention_Pharmacological
venlafaxine
36621
Intervention_Pharmacological
clonidine
36622
Intervention_Pharmacological
Venlafaxine
36623
Intervention_Pharmacological
venlafaxine
36624
Intervention_Pharmacological
clonidine
36625
Intervention_Pharmacological
Venlafaxine
36626
Intervention_Pharmacological
clonidine
36627
Intervention_Pharmacological
venlafaxine
36628
Outcome_Physical
hot flashes
36629
Outcome_Physical
severe hot flashes ( HF )
36630
Outcome_Adverse-effects
side effects
36631
Outcome_Other
efficacy
36632
Outcome_Other
quality of life
36633
Outcome_Physical
sexual functioning
36634
Outcome_Physical
HF frequency and severity
36635
Outcome_Adverse-effects
, side effects ,
36636
Outcome_Other
quality of life
36637
Outcome_Adverse-effects
and
36638
Outcome_Physical
sexuality
36639
Outcome_Physical
toxicity
36640
Outcome_Adverse-effects
side effects
36641
Outcome_Physical
Median reduction in HF score
36642
Outcome_Physical
HF reduction
36643
Outcome_Adverse-effects
Side effects
36644
Participant_Condition
treatment of hot flashes in breast cancer patients
36645
Participant_Condition
Breast cancer
36646
Participant_Condition
menopause
36647
Participant_Condition
severe hot flashes ( HF )
36648
Participant_Sample-size
60
36649
Participant_Condition
breast cancer patients
36650
Participant_Condition
HF
36651
Participant_Sample-size
Thirty patients